Adaptive Biotechnologies Corporation
NasdaqGS:ADPT Lagerbericht
Marktkapitalisierung: US$875.1m
Adaptive Biotechnologies Zukünftiges Wachstum
Future Kriterienprüfungen 1/6 Adaptive Biotechnologies wird ein jährliches Gewinn- und Umsatzwachstum von 24.9% bzw. 17.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 26.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -93% betragen.
Wichtige Informationen
24.9%
Wachstumsrate der Gewinne
Life Sciences Gewinnwachstum 18.8% Wachstumsrate der Einnahmen 17.5% Zukünftige Eigenkapitalrendite -93.0% Analystenabdeckung Good
Zuletzt aktualisiert 11 Nov 2024
Jüngste Aktualisierungen zum künftigen Wachstum
Price target increased by 7.9% to US$6.83 Aug 05
Price target decreased by 7.3% to US$6.33 May 09
Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024 Apr 03
Consensus revenue estimates fall by 21% Feb 22
Consensus revenue estimates fall by 21% Feb 21
Consensus revenue estimates fall by 21% Feb 21
Alle Updates anzeigen
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 08
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet? Nov 01
Adaptive Biotechnologies Corporation to Report Q3, 2024 Results on Nov 07, 2024 Oct 10
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher Oct 05
Adaptive Announces IVDR Certification for clonoSEQ® in European Union Aug 29
Senior VP notifies of intention to sell stock Aug 25
Price target increased by 7.9% to US$6.83 Aug 05
Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat Aug 02
Adaptive Biotechnologies Corporation to Report Q2, 2024 Results on Aug 01, 2024 Jul 12
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk Jul 12
Price target decreased by 7.3% to US$6.33 May 09
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 08
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt? May 08
New minor risk - Shareholder dilution Apr 28
Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 07, 2024 Apr 28
Adaptive Biotechnologies Corporation to Report Q1, 2024 Results on May 07, 2024 Apr 19
Adaptive Biotechnologies Corporation Announces CFO Changes Apr 04
It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks Apr 03
Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024 Apr 03
Insufficient new directors Apr 01
Co-Founder recently sold US$167k worth of stock Mar 07
Adaptive Biotechnologies: A Post Earnings Assessment Feb 25
Consensus revenue estimates fall by 21% Feb 22
Consensus revenue estimates fall by 21% Feb 21
Consensus revenue estimates fall by 21% Feb 21
Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically Feb 17
Full year 2023 earnings: EPS and revenues miss analyst expectations Feb 15
Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25% Feb 01
Adaptive Biotechnologies Corporation to Report Q4, 2023 Results on Feb 14, 2024 Jan 30
Adaptive Biotechnologies Corporation and Collaborators to Present More Than 30 Abstracts Demonstrating the Actionability of ClonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th Annual Meeting Dec 05
Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be Nov 17
Consensus revenue estimates fall by 12% Nov 16
Price target decreased by 15% to US$10.00 Nov 15
Adaptive Biotechnologies Corporation Updates Revenue Guidance for the Full Year 2023 Nov 12
Price target decreased by 8.0% to US$11.43 Nov 10
Adaptive Biotechnologies Corporation to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment? Oct 13
Adaptive Biotechnologies Corporation Announces Launch of Epic Integration for ClonosEQ Sep 14 Adaptive Biotechnologies Corporation Announces Executive Changes
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 04
New minor risk - Share price stability Jul 13
Adaptive Biotechnologies Corporation to Report Q2, 2023 Results on Aug 02, 2023 Jul 12
Adaptive Biotechnologies Corporation to Report Q2, 2023 Results on Aug 02, 2023 Jul 11
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment? Jul 06
Insufficient new directors Jun 20
Chief Financial Officer notifies of intention to sell stock Jun 19
Adaptive Biotechnologies Corporation Announces Resignation of Leslie Trigg from the Board Jun 15
New minor risk - Insider selling Jun 08
Chief Financial Officer recently sold US$272k worth of stock Jun 08
Adaptive Biotechnologies Highlights New Data At ASCO 2023 and EHA 2023 Underscoring the Clonoseq® Assay's Impact as A Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer Jun 03
Adaptive Biotechnologies Corporation Announces FDA Acceptance of Genentech's Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology May 10
Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding May 05
Adaptive Biotechnologies Corporation Provides Revenue Guidance for the Full Year 2023 May 05
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 05
We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely Apr 15
President recently sold US$194k worth of stock Mar 09
Adaptive Biotechnologies Corporation Provides Revenue Guidance for Full Year 2023 Feb 16
Full year 2022 earnings: EPS exceeds analyst expectations Feb 16
Adaptive Biotechnologies Corporation to Report Q4, 2022 Results on Feb 14, 2023 Jan 24
Price target increased to US$13.00 Dec 22
Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans Dec 13
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease in Patients with Diffuse Large B-Cell Lymphoma Using Circulating Tumor DNA Dec 03
Price target decreased to US$12.07 Nov 16
Chief Commercial Officer of MRD notifies of intention to sell stock Nov 05
Third quarter 2022 earnings: EPS exceeds analyst expectations Nov 04
Adaptive Biotechnologies Corporation Provides Revenue Guidance for the Full Year 2022 Nov 04
Price target decreased to US$13.21 Oct 31
Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system Oct 11
Adaptive Biotechnologies Corporation to Report Q3, 2022 Results on Nov 03, 2022 Oct 06
Adaptive Biotechnologies announces $250M non-dilutive royalty financing Sep 12
We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate Aug 14
Chief Commercial Officer of MRD recently sold US$193k worth of stock Aug 07
Price target decreased to US$14.58 Aug 06
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 04
Adaptive Biotechnologies Corporation Reiterates Revenue Guidance for the Full Year 2022 Aug 04
Adaptive Biotechnologies Corporation to Report Q2, 2022 Results on Aug 03, 2022 Jul 09
Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease Jun 16
Adaptive Biotechnologies Corporation Includes in Several Abstracts Investigating the Impact of Mrd in Blood Cancers At the American Society of Clinical Oncology Jun 04
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat May 06
Adaptive Biotechnologies Corporation Reiterates Revenue Guidance for the Full Year 2022 May 05
Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth Apr 29
Price target decreased to US$32.00 Apr 27 Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 10, 2022 Apr 23
Adaptive Biotechnologies: Good Buy For Long-Term Investors Apr 15
Adaptive Biotechnologies Corporation to Report Q1, 2022 Results on May 04, 2022 Apr 06
Now 24% undervalued after recent price drop Apr 05
Co-Founder exercised options and sold US$243k worth of stock Mar 17
President recently sold US$55k worth of stock Mar 11
Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%? Feb 26
Adaptive Biotechnologies Corporation Announces New Data Demonstrating ImmunoSEQ® Technology Can Identify T-Cell Receptors Associated with Crohn’s Disease Feb 19
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 16 Adaptive Biotechnologies Corporation Announces CFO Changes
Price target decreased to US$46.20 Feb 15
Price target decreased to US$52.00 Jan 12
We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth Jan 09
Gewinn- und Umsatzwachstumsprognosen NasdaqGS:ADPT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions) Datum Umsatz Gewinne Freier Cashflow Bargeld aus operativen Tätigkeiten Durchschn. Anz. Analysten 12/31/2026 259 -103 -29 -96 6 12/31/2025 209 -141 -57 -127 8 12/31/2024 177 -165 -73 -122 6 9/30/2024 177 -195 -115 -110 N/A 6/30/2024 169 -213 -137 -129 N/A 3/31/2024 175 -215 -145 -136 N/A 12/31/2023 170 -225 -167 -156 N/A 9/30/2023 180 -196 -171 -159 N/A 6/30/2023 190 -191 -170 -155 N/A 3/31/2023 184 -195 -195 -179 N/A 12/31/2022 185 -200 -200 -184 N/A 9/30/2022 168 -221 -231 -208 N/A 6/30/2022 160 -232 -241 -209 N/A 3/31/2022 155 -229 -248 -199 N/A 12/31/2021 154 -207 -254 -193 N/A 9/30/2021 147 -190 -241 -179 N/A 6/30/2021 133 -171 -234 -182 N/A 3/31/2021 116 -155 -208 -176 N/A 12/31/2020 98 -146 -168 -150 N/A 9/30/2020 92 -122 -148 -137 N/A 6/30/2020 92 -99 -131 -120 N/A 3/31/2020 93 -82 -115 -105 N/A 12/31/2019 85 -70 194 205 N/A 9/30/2019 78 -62 215 227 N/A 6/30/2019 69 -56 235 245 N/A 3/31/2019 59 -53 243 252 N/A 12/31/2018 56 -46 -39 -32 N/A 12/31/2017 38 -43 N/A -35 N/A
Mehr anzeigen
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ADPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: ADPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: ADPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: ADPTDie Einnahmen des Unternehmens (17.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).
Hohe Wachstumseinnahmen: ADPTDie Einnahmen des Unternehmens (17.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ADPT wird voraussichtlich in 3 Jahren unrentabel sein.
Wachstumsunternehmen entdecken Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
